VarmX
Biotechnology ResearchView the employees at
VarmX-
Michael Zörer Head of Clinical Operations at VarmX
-
Vienna, Vienna, Austria
-
Top 10%
Tainá Gomes R&D Scientist at VarmX-
Netherlands
-
Rising Star
Gerard Short CMO and Clinical Development Physician in Gene Therapy, Rare and Haematological Disease-
Greater Cambridge Area Contact Info
-
Top 5%
Overview
VarmX (www.varmx.com) is a young Leiden based biotech company that is focusing on the development of therapies in the field of hemostasis and thrombosis. Originally a spin-off from the Leiden University Medical Center (LUMC), our mission is to develop and manufacture therapeutic proteins to restore hemostasis. Our lead compound, VMX-C001, is intended to safely and effectively restore hemostasis in case of bleeding or emergency surgery in patients taking so-called oral factor Xa inhibitors. The VarmX program has gained significant interest in the investment community and a very successful Series B financing round of €32 mill. was closed in 2020. This round was followed by a Series B2 round of €32 mill. in May 2023 allowing the company to further progress the lead program towards Investigational New Drug (IND) approval and prepare for pivotal trials.
-